New hope for tough leukemia: experimental drug BL-M11D1 enters human testing
NCT ID NCT05924750
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called BL-M11D1 in 130 adults whose acute myeloid leukemia has returned or not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Participants must have a specific marker (CD33) on their leukemia cells and be in relatively good health.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Anhui Provincial Hospital
NOT_YET_RECRUITINGHefei, Anhui, China
-
Beijing Hospital
NOT_YET_RECRUITINGBeijing, Beijing Municipality, China
-
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
RECRUITINGTianjin, Tianjin Municipality, 300020, China
-
Institute of Hematology, the First Hospital of Harbin
NOT_YET_RECRUITINGHaerbin, Heilongjiang, China
-
Qilu Hospital of Shandong University
NOT_YET_RECRUITINGJinan, Shangdong, China
-
Shanghai Tongji Hospital
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, China
-
Shengjing Hospital of China Medical University
NOT_YET_RECRUITINGShenyang, Liaoning, China
-
West China Hospital，Sichuan University
NOT_YET_RECRUITINGChengdu, Sichuan, China